Keenova Therapeutics plc Income Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 27, 2024	FY2023 1 months to Dec 29, 2023	FY2022 6 months to Dec 30, 2022	FY2021 12 months to Dec 31, 2021
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Combination, integration, and other related expenses
Research and development expenses
Restructuring charges, net
Restructuring (credits) charges, net
Non-restructuring impairment charges
Opioid-Related Litigation Settlement loss
Medicaid lawsuit charge
Liabilities management and separation costs
Operating loss
Interest expense
Interest income
(Loss) gain on divestiture (Note 6)
Gain (loss) on debt extinguishment, net
Other income (expense), net
Reorganization items, net
(Loss) income from continuing operations before income taxes
Income tax (benefit) expense
(Loss) income from continuing operations
(Loss) income from discontinued operations, net of tax
Net (loss) income
Basic (loss) income per share (Note 10):
(Loss) income from continuing operations (in dollars per share)
(Loss) income from discontinued operations, net of tax (in dollars per share)
Net (loss) income (in dollars per share)
Basic weighted-average shares outstanding (in shares)
Diluted (loss) income per share (Note 10):
(Loss) income from continuing operations (in dollars per share)
(Loss) income from discontinued operations, net of tax (in dollars per share)
Net (loss) income (in dollars per share)
Diluted weighted-average shares outstanding (in shares)
Discontinued Operation, Tax Effect of Discontinued Operation

Comments